Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | ESRRB | O95718 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESRRG | P62508 | 2/20 | 0.33 |
| ▸ | ME3 | Q16798 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FPR1 | P21462 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738663 | 0.98 | FASN (0.51) | FASNTDP1HTR7SIGMAR1OPRM1 | |
| SCHEMBL737742 | 0.96 | FASN (0.50) | FASNTDP1HTR7SIGMAR1OPRM1 | |
| SCHEMBL738435 | 0.96 | FASN (0.53) | FASNTDP1HTR7SIGMAR1OPRM1 | |
| SCHEMBL738813 | 0.81 | FASN (0.48) | FASNSIGMAR1OPRM1HRH3 | |
| SCHEMBL737143 | 0.81 | FASN (0.47) | FASNHRH3 | |
| SCHEMBL736592 | 0.80 | FASN (0.49) | FASNHRH3 | |
| SCHEMBL735789 | 0.79 | FASN (0.48) | FASNSIGMAR1OPRM1HRH3 | |
| SCHEMBL735677 | 0.79 | SIGMAR1 (0.52) | FASNTDP1HTR7SIGMAR1OPRM1 | |
| SCHEMBL737496 | 0.78 | FASN (0.47) | FASNSIGMAR1OPRM1HRH3 | |
| SCHEMBL15587566 | 0.78 | FASN (0.77) | FASNTDP1HTR7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | FASN 4745/4885TDP1 3955/4885HTR7 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.